Active Ingredient History
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Non-Small-Cell Lung (Phase 2)
Fibrosarcoma (Phase 2)
Glioblastoma (Phase 2)
Hemangiosarcoma (Phase 2)
Intestinal Neoplasms (Phase 2)
Leiomyosarcoma (Phase 2)
Liposarcoma (Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms ()
Neurofibrosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma ()
Sarcoma, Synovial (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
